Clinical Trials on Sedative Intoxication in Finland

Total 120 results

Butler Hospital

Completed

A Machine Learning Approach for Inferring Alcohol Intoxication Levels From Gait Data (Alcogait)

Alcohol Drinking

United States
Helsinki University Central Hospital

Completed

Assessment of Sedation During Endoscopy

Sedation

Finland
University of Turku

Completed

Bioavailability of Dexmedetomidine After Intranasal Administration (INDEX)

Sedation

Finland
Turku University Hospital
University of Turku

Completed

Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients (PINDEX)

Procedural Sedation

Finland
Brown University
National Institute on Drug Abuse (NIDA)

Completed

Motivational Interviews for Incarcerated Teens - 1

Marijuana Abuse | Alcoholic Intoxication

United States
Helsinki University Central Hospital

Completed

Target-controlled Infusion Versus Patient-controlled Sedation With Propofol in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Sedation

Finland
Brown University

Completed

Improving Smoking Cessation Outcomes in Heavy Drinkers - 1

Tobacco Use Disorder

United States
Orion Corporation, Orion Pharma

Completed

Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU (DEX PK)

Pharmacokinetics | Sedation

Finland
Orion Corporation, Orion Pharma

Terminated

Dexmedetomidine for Continuous Sedation

Conscious Sedation

Finland, Switzerland
Helsinki University Central Hospital

Completed

Doxapram as an Additive to Propofol Sedation in Sedation for ERCP

Hypoxia | Sedation

Finland
Finnish Institute for Health and Welfare
European Commission; Hospital District of Helsinki and Uusimaa

Unknown

Alcohol and Other Psychoactive Substances in Road Traffic - a Case-control Study

Prevalence of Psychoactive Substances in Road Traffic | Psychoactive Substances in Accident Involved Drivers | Relative Risk Estimation of Accident Involvement for Impaired Drivers

Finland
Helsinki University Central Hospital

Unknown

Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines (Ty21a-ASC)

Healthy

Finland
University of Turku
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

EUpertstrain 4 Study of Bordetella Pertussis Isolates

Bordetella Pertussis, Whooping Cough

Finland
Helsinki University Central Hospital
University of Helsinki

Recruiting

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera | Typhoid Fever | Vaccine-Preventable Diseases

Finland
Tampere University

Completed

Helicobacter Pylori and Acute Alcohol Induced Pancreatitis

Helicobacter Infections | Pancreatitis, Acute

Finland
Turku University Hospital

Completed

Study of Lyme Neuroborreliosis

Lyme Neuroborreliosis

Finland
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Tetanus | Diphtheria | Acellular Pertussis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Meningococcal Infections

Finland
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Infections, Meningococcal

Finland
University of Oxford
University of Turku; National Institute for Public Health and the Environment...

Completed

A Study Exploring Whooping Cough Protection in Children and Adults (BERT)

Pertussis

United Kingdom, Finland, Netherlands
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Infections, Meningococcal

Finland
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Brown University

Completed

Dismantling Mindfulness: Contributions of Attention vs. Acceptance

Mild-moderate Unipolar Depression; Persistent Negative Affect

United States
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Orion Corporation, Orion Pharma

Completed

Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU) (MIDEX)

Continuous Sedation in Initially Sedated Adults in ICU

Netherlands, Belgium, Estonia, Finland, France, Germany, Norway, Switzerland, United Kingdom
Orion Corporation, Orion Pharma

Completed

Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) (Prodex)

Continuous Sedation in Initially Sedated Adults in ICU

Finland, United Kingdom, Belgium, Germany, Netherlands, Russian Federation, Switzerland
Butler Hospital
National Institute on Drug Abuse (NIDA)

Completed

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

HCV Negative Status | HCV Risk Behavior

United States
T2 Biosystems

Terminated

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Lyme Disease

United States
University of Prince Edward Island
The Queen Elizabeth Hospital

Completed

The Feasibility of Pertussis Immunization in a Canadian Emergency Department

Pertussis

Canada
Hoosier Cancer Research Network
Clovis Oncology, Inc.

Completed

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Breast Cancer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
Hoffmann-La Roche

Completed

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Israel, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more
Pfizer
Valneva Austria GmbH

Active, not recruiting

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Lyme Borreliosis

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); American College of Radiology Imaging Network

Active, not recruiting

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

Stage II Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Sweden
GlaxoSmithKline

Completed

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Infections, Meningococcal

United States, Finland, Poland
Pfizer

Completed

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Lyme Borreliosis

United States, Germany, Belgium
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.

Active, not recruiting

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Triple Negative Breast Cancer

United States, Canada
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain, Sweden
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Infections, Meningococcal

Finland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras

Clinical Trials on Sedative Intoxication in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations